Navigation Links
ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB) today announced that data relating to its proprietary PC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment of Type 2 diabetes will be presented at the 67th Scientific Sessions of the American Diabetes Association (ADA) to be held June 22-26, 2007 in Chicago, IL. The ADA's annual Scientific Sessions meeting is one of the largest gatherings of health care professionals involved in diabetes research and the delivery of diabetes care.

"These encouraging results from our Phase I/II multiple-dose clinical studies demonstrate that our PC-DAC(TM):Exendin-4 Albumin Conjugate is a well-tolerated and effective therapy," said Mark D. Perrin, President and CEO. "The data was further evidence of our compound's potential to become a once-weekly treatment for Type 2 diabetes."

The study titled "PC-DAC(TM):Exendin-4 (CJC-1134-PC) Demonstrates Safety and Efficacy as an Adjunct Therapy to Metformin: A Randomized, Double-Blind, Placebo-Controlled, One Month Phase I/II Study in 70 Patients with Type 2 Diabetes Mellitus", authored by Maggie Wang et al., was featured as a late breaking abstract. Seventy patients were enrolled in US and Canada and randomized to 1 mg, 2mg, 3mg of PC-DAC(TM):Exendin-4 or placebo treatment groups. All three treatment groups experienced reductions in fasting plasma glucose that were statistically significant versus baseline (p less than 0.005) and versus placebo (p less than 0.03) over the 5-week treatment period. Median HbA1c values decreased from baseline by 0.7%, 0.8% and 0.9% in the 1mg, 2mg, and 3mg groups, respectively, at the end of the study (Day 63) and were statistically significant (p less than 0.03 by ANCOVA) between pooled active patients (n=52) and placebo (n=18). There was no significant change in weight in the treatment cohorts (baseline 81-85kg) at the end of the treatment period. Generally low-titer antibodies were de tected in 11/52 treated patients. The drug was well-tolerated with no drug-related serious adverse events during the study.

In addition, the study titled "Safety and Pharmacodynamics of CJC-1134-PC, a Novel GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study", authored by Maggie Wang et al., was also featured as a poster session. This study evaluated the safety and efficacy of escalating single doses of CJC-1134-PC in 58 patients who had discontinued their oral antidiabetic agents for greater than or equal to 1 week and were randomized to either active drug or placebo in 6 escalating cohorts (PC-DAC(TM):Exendin-4 from 0.31mg to 5.0mg). Doses of greater than or equal to 1.25mg produced rapid and long-lasting reductions in mean daily glucose and fasting plasma glucose levels, persisting for at least 7 days after the single injection. In a separate cohort of 16 patients (12 active and 4 placebo) treated with either a single dose of 3mg PC-DAC(TM):Exendin-4 or placebo, a mean reduction in body weight of 2.5 kg (vs. 1.2 kg for placebo) was observed at the end of the 3-week in-clinic stay on a controlled diet. No significant safety or tolerability issues were reported at dose levels up to 3 mg.

Abstracts for the event can be found on the ADA's website at http://scientificsessions.diabetes.org

About PC-DAC(TM):Exendin-4

Exendin-4, like Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon and increases insulin secretion in a glucose-dependent manner. Exendin-4 may stimulate beta-cell proliferation, restore beta-cell sensitivity to glucose, delay gastric emptying, and increase peripheral sensitivity to glucose. The clinical util ity of Exendin-4 is somewhat limited by its relatively short half-life in plasma. Developed with ConjuChem's proprietary PC-DAC(TM) technology, PC-DAC(TM):Exendin-4 is a modified Exendin-4 analogue that is covalently bound to recombinant human albumin (Recombumin(R), provided by Novozymes Delta Limited). Data from Phase I/II clinical studies have demonstrated that the preformed albumin-peptide conjugate has a much longer half-life than the peptide alone. The product is a highly soluble liquid formulation that is injectable in a small volume with a small gauge needle.

About ConjuChem

ConjuChem, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic DAC(TM) and PC-DAC(TM) Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide. Detailed descriptions of the Company can be viewed on the Company's website http://www.conjuchem.com.

-30-

/For further information: Lennie Ryer, CA, Vice President Finance, CFO, ConjuChem Biotechnologies Inc., (514) 844-5558 ext 224, mpolonsky@equicomgroup.com


'"/>




Related medicine technology :

1. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
2. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):